LTRN Lantern Pharma Inc.
Healthcare$3.38-3.43%ClosedMarket Cap: $43.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
11.43
P/S
0.00
EV/EBITDA
-2.40
DCF Value
$398.63
FCF Yield
-33.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1.0%
ROA
-220.3%
ROIC
-473.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-3.4M | $-3.3M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.2M | $-4.1M | $— | — |
| FY null | $0.00 | NaN% | $-18.0M | $-17.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.3M | $-4.2M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.7M | $-4.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-4.8M | $-4.5M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-5.9M | $-5.9M | $— | — |
| FY null | $0.00 | NaN% | $-22.2M | $-20.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-5.2M | $-4.5M | $— | — |
| Q2 null | $0.00 | NaN% | $-5.4M | $-5.0M | $— | — |
| Q1 null | $0.00 | NaN% | $-5.7M | $-5.4M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-4.9M | $-4.2M | $-0.39 | — |